Metabolic syndrome among HIV-infected Taiwanese patients in the era of highly active antiretroviral therapy: Prevalence and associated factors

Journal of Antimicrobial Chemotherapy

Volumn 67, Issue 4, 2012, Pages 1001-1009

  Wu, Pei Ying ^a   Hung, Chien Ching ^a   Liu, Wen Chun ^a   Hsieh, Chia Yin ^a   Sun, Hsin Yun ^a   Lu, Ching Lan ^a   Wu, Hsiu ^b   Chien, Kuo Liong ^a,c  

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^b CENTER FOR DISEASE CONTROL   (Taiwan)

^c NATIONAL TAIWAN UNIVERSITY   (Taiwan)

Author keywords

Hyperlipidaemia; Non nucleoside reverse transcriptase inhibitors; Nucleoside reverse transcriptase inhibitors; Protease inhibitors; Survey

Indexed keywords

ABACAVIR; ABACAVIR PLUS LAMIVUDINE; ATAZANAVIR; DARUNAVIR; DEOXYCYTIDINE; DIDANOSINE; EFAVIRENZ; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; INDINAVIR; LAMIVUDINE; LAMIVUDINE PLUS ZIDOVUDINE; LOPINAVIR PLUS RITONAVIR; NELFINAVIR; NEVIRAPINE; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; TIPRANAVIR; ZIDOVUDINE;

ADULT; AGE; ARTICLE; ASIAN; CARDIOVASCULAR DISEASE; CD4 LYMPHOCYTE COUNT; CLINICAL ASSESSMENT TOOL; CROSS-SECTIONAL STUDY; DIABETES MELLITUS; DISEASE COURSE; FAMILY HISTORY; FEMALE; GENDER; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HOMOSEXUALITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERTENSION; INFORMATION PROCESSING; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; MODIFIED ADULT TREATMENT PANEL III; PREVALENCE; SMOKING; TAIWAN; VIRUS LOAD; WAIST CIRCUMFERENCE;

ADULT; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; ASIAN CONTINENTAL ANCESTRY GROUP; CROSS-SECTIONAL STUDIES; ETHNIC GROUPS; FEMALE; HIV INFECTIONS; HUMANS; MALE; METABOLIC SYNDROME X; MIDDLE AGED; PREVALENCE; TAIWAN;

EID: 84863388326     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkr558     Document Type: Article

References (48)

1. Lohse N, Hansen AB, Pedersen G et al. Survival of persons with and without HIV infection in Denmark, 1995-2005. Ann Intern Med 2007; 146: 87-95.
2. Sterne JA, Hernan MA, Ledergerber B et al. Long-term effectiveness of potent antiretroviral therapy in preventing AIDS and death: a prospective cohort study. Lancet 2005; 366: 378-84.
3. Calza L, Manfredi R, Farneti B et al. Incidence of hyperlipidaemia in a cohort of 212 HIV-infected patients receiving a protease inhibitor-based antiretroviral therapy. Int J Antimicrob Agents 2003; 22: 54-9.
4. Brown TT, Cole SR, Li X et al. Antiretroviral therapy and the prevalence and incidence of diabetes mellitus in the multicenter AIDS cohort study. Arch Intern Med 2005; 165: 1179-84.
5. Seaberg EC, Munoz A, Lu M et al. Association between highly active antiretroviral therapy and hypertension in a large cohort of men followed from 1984 to 2003. AIDS 2005; 19: 953-60.
6. Friis-Moller N, Reiss P, Sabin CA et al. Class of antiretroviral drugs and the risk of myocardial infarction. N Engl J Med 2007; 356: 1723-35.
7. Saint-Marc T, Partisani M, Poizot-Martin I et al. A syndrome of peripheral fat wasting (lipodystrophy) in patients receiving long-term nucleoside analogue therapy. AIDS 1999; 13: 1659-67.
8. Riddler SA, Smit E, Cole SR et al. Impact of HIV infection and HAART on serum lipids in men. JAMA 2003; 289: 2978-82.
9. Riddler SA, Li X, Chu H et al. Longitudinal changes in serum lipids among HIV-infected men on highly active antiretroviral therapy. HIV Med 2007; 8: 280-7.
10. Tien PC, Schneider MF, Cole SR et al. Antiretroviral therapy exposure and incidence of diabetes mellitus in the Women's Interagency HIV Study. AIDS 2007; 21: 1739-45.
11. Ledergerber B, Furrer H, Rickenbach M et al. Factors associated with the incidence of type 2 diabetes mellitus in HIV-infected participants in the Swiss HIV Cohort Study. Clin Infect Dis 2007; 45: 111-9.
12. Lo YC, Chen MY, Sheng WH et al. Risk factors for incident diabetes mellitus among HIV-infected patients receiving combination antiretroviral therapy in Taiwan: a case-control study. HIV Med 2009; 10: 302-9.
13. Boccara F. Cardiovascular complications and atherosclerotic manifestations in the HIV-infected population: type, incidence and associated risk factors. AIDS 2008; 22 Suppl 3: S19-26.
14. Friis-Moller N, Sabin CA, Weber R et al. Combination antiretroviral therapy and the risk of myocardial infarction. N Engl J Med 2003; 349: 1993-2003.
15. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002; 106: 3143-421.
16. Jerico C, Knobel H, Montero M et al. Metabolic syndrome among HIV-infected patients: prevalence, characteristics, and related factors. Diabetes Care 2005; 28: 132-7.
17. Samaras K, Wand H, Law M et al. Prevalence of metabolic syndrome in HIV-infected patients receiving highly active antiretroviral therapy using International Diabetes Foundation and Adult Treatment Panel III criteria: associations with insulin resistance, disturbed body fat compartmentalization, elevated C-reactive protein, and [corrected] hypoadiponectinemia. Diabetes Care 2007; 30: 113-9.
18. Mondy K, Overton ET, Grubb J et al. Metabolic syndrome in HIV-infected patients from an urban, midwestern US outpatient population. Clin Infect Dis 2007; 44: 726-34.
19. Sobieszczyk ME, Hoover DR, Anastos K et al. Prevalence and predictors of metabolic syndrome among HIV-infected and HIV-uninfected women in the Women's Interagency HIV Study. J Acquir Immune Defic Syndr 2008; 48: 272-80.
20. Hansen BR, Petersen J, Haugaard SB et al. The prevalence of metabolic syndrome in Danish patients with HIV infection: the effect of antiretroviral therapy. HIV Med 2009; 10: 378-87.
21. Squillace N, Zona S, Stentarelli C et al. Detectable HIV viral load is associated with metabolic syndrome. J Acquir Immune Defic Syndr 2009; 52: 459-64.
22. Worm SW, Friis-Moller N, Bruyand M et al. High prevalence of the metabolic syndrome in HIV-infected patients: impact of different definitions of the metabolic syndrome. AIDS 2010; 24: 427-35.
23. Gazzaruso C, Sacchi P, Garzaniti A et al. Prevalence of metabolic syndrome among HIV patients. Diabetes Care 2002; 25: 1253-4.
24. Bonfanti P, Ricci E, de Socio G et al. Metabolic syndrome: a real threat for HIV-positive patients?: Results from the SIMONE study. J Acquir Immune Defic Syndr 2006; 42: 128-31.
25. Jacobson DL, Tang AM, Spiegelman D et al. Incidence of metabolic syndrome in a cohort of HIV-infected adults and prevalence relative to the US population (National Health and Nutrition Examination Survey). J Acquir Immune Defic Syndr 2006; 43: 458-66.
26. Bureau of Health Promotion DoH, ROC (Taiwan). Adult (20 yr). The definitions of metabolic syndrome (2007). http://www.bhp.doh.gov.tw/BHPnet/Portal/Them_Show.aspx?Subject=200712250023&Class=2&No=200712250123 (31 March 2011, date last accessed).
27. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001; 285: 2486-97.
28. Grundy SM, Cleeman JI, Daniels SR et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute scientific statement. Circulation 2005; 112: 2735-52.
29. Gazzaruso C, Bruno R, Garzaniti A et al. Hypertension among HIV patients: prevalence and relationships to insulin resistance and metabolic syndrome. J Hypertens 2003; 21: 1377-82.
30. Hwang LC, Bai CH, Chen CJ. Prevalence of obesity and metabolic syndrome in Taiwan. J Formos Med Assoc 2006; 105: 626-35.
31. Elzi L, Marzolini C, Furrer H et al. Treatment modification in human immunodeficiency virus-infected individuals starting combination antiretroviral therapy between 2005 and 2008. Arch Intern Med 2010; 170: 57-65.
32. Rimland D, Guest JL, Hernandez-Ramos I et al. Antiretroviral therapy in HIV-positive women is associated with increased apolipoproteins and total cholesterol. J Acquir Immune Defic Syndr 2006; 42: 307-13.
33. Klein D, Hurley LB, Quesenberry CP Jr et al. Do protease inhibitors increase the risk for coronary heart disease in patients with HIV-1 infection? J Acquir Immune Defic Syndr 2002; 30: 471-7.
34. Bergersen BM, Sandvik L, Bruun JN et al. Elevated Framingham risk score in HIV-positive patients on highly active antiretroviral therapy: results from a Norwegian study of 721 subjects. Eur J Clin Microbiol Infect Dis 2004; 23: 625-30.
35. Mangili A, Jacobson DL, Gerrior J et al. Metabolic syndrome and subclinical atherosclerosis in patients infected with HIV. Clin Infect Dis 2007; 44: 1368-74.
36. Gallant JE, Staszewski S, Pozniak AL et al. Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial. JAMA 2004; 292: 191-201.
37. Williams P, Wu J, Cohn S et al. Improvement in lipid profiles over 6 years of follow-up in adults with AIDS and immune reconstitution. HIV Med 2009; 10: 290-301.
38. Montes ML, Pulido F, Barros C et al. Lipid disorders in antiretroviral-naive patients treated with lopinavir/ritonavir-based HAART: frequency, characterization and risk factors. J Antimicrob Chemother 2005; 55: 800-4.
39. Silva EF, Bassichetto KC, Lewi DS. Lipid profile, cardiovascular risk factors and metabolic syndrome in a group of AIDS patients. Arq Bras Cardiol 2009; 93: 113-8.
40. Ribera E, Paradineiro JC, Curran A et al. Improvements in subcutaneous fat, lipid profile, and parameters of mitochondrial toxicity in patients with peripheral lipoatrophy when stavudine is switched to tenofovir (LIPOTEST study). HIV Clin Trials 2008; 9: 407-17.
41. Sattler FR. Pathogenesis and treatment of lipodystrophy: what clinicians need to know. Top HIV Med 2008; 16: 127-33.
42. McComsey GA, Paulsen DM, Lonergan JT et al. Improvements in lipoatrophy, mitochondrial DNA levels and fat apoptosis after replacing stavudine with abacavir or zidovudine. AIDS 2005; 19: 15-23.
43. Martin A, Smith DE, Carr A et al. Reversibility of lipoatrophy in HIV-infected patients 2 years after switching from a thymidine analogue to abacavir: the MITOX Extension Study. AIDS 2004; 18: 1029-36.
44. Brinkman K, Smeitink JA, Romijn JA et al. Mitochondrial toxicity induced by nucleoside-analogue reverse-transcriptase inhibitors is a key factor in the pathogenesis of antiretroviral-therapy-related lipodystrophy. Lancet 1999; 354: 1112-5.
45. Arranz Caso JA, Lopez JC, Santos I et al. A randomized controlled trial investigating the efficacy and safety of switching from a protease inhibitor to nevirapine in patients with undetectable viral load. HIV Med 2005; 6: 353-9.
46. Negredo E, Cruz L, Paredes R et al. Virological, immunological, and clinical impact of switching from protease inhibitors to nevirapine or to efavirenz in patients with human immunodeficiency virus infection and long-lasting viral suppression. Clin Infect Dis 2002; 34: 504-10.
47. van Leth F, Phanuphak P, Stroes E et al. Nevirapine and efavirenz elicit different changes in lipid profiles in antiretroviral-therapy-naive patients infected with HIV-1. PLoS Med 2004; 1: e19.
48. Martinez E, Garcia-Viejo MA, Blanco JL et al. Impact of switching from human immunodeficiency virus type 1 protease inhibitors to efavirenz in successfully treated adults with lipodystrophy. Clin Infect Dis 2000; 31: 1266-73.